Bhupendra Singh
Bhupendra Singh has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Amir Raza
School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
2 shared publications Bharat Jhanwar
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, India
2 shared publications- Abhinav Anand
Department of Pharmacy, CT Institute of Pharmaceutical Sciences, CT Group of Institutions, Jalandhar,144020, India
1 shared publication - Amit Chaudhary
Chitkara University School of Pharmacy, Chitkara University, Baddi, Himachal Pradesh, 174103, India
1 shared publication - Anchal Sharma
School of Pharmacy, Abhilashi University Chailchowk, India
1 shared publication Ankit Saini
Bhardwaj India Private Limited, New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 4 (42) , 1518
Navigating Advances and Challenges in Pharmaceutical Impurity Characterization and Quantification
Impurities are unavoidable foreign materials present in trace amounts in pharmaceuticals. Regulatory authorities like the FDA and EMA set guidelines to control impurity levels, ensuring drug safety and efficacy. Impurity profiling, which includes isolating, identifying, and characterizing impurities, is essential in maintaining these standards. The increasing complexity of drug formulations, due to advanced synthetic methods, novel excipients, and delivery systems like nanoparticles and liposomes, has led to more impurities. Analytical methods such as HPLC, GC, MS, NMR, FTIR, and hyphenated methods are used to detect and quantify impurities with extended accuracy and sensitivity.This review aims to explore both current and advanced methods for impurity detection, with a focus on recent advancements in analytical techniques and the complexity of formulations. It also examines the challenges of impurity detection, considering existing resources and newly updated regulatory guidelines for impurity control. This review aims to highlight the critical need for improved analytical techniques that minimize errors in impurity detection and enhance accuracy. Stringent regulatory guidelines and advanced analytical techniques like HPLC, MS, and NMR are vital for ensuring drug safety and quality. Continuous innovation in impurity analysis will be crucial to meet evolving standards.
- 31 August 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 4 (42) , 1518
Open AccessNavigating Advances and Challenges in Pharmaceutical Impurity Characterization and Quantification
Impurities are unavoidable foreign materials present in trace amounts in pharmaceuticals. Regulatory authorities like the FDA and EMA set guidelines to control impurity levels, ensuring drug safety and efficacy. Impurity profiling, which includes isolating, identifying, and characterizing impurities, is essential in maintaining these standards. The increasing complexity of drug formulations, due to advanced synthetic methods, novel excipients, and delivery systems like nanoparticles and liposomes, has led to more impurities. Analytical methods such as HPLC, GC, MS, NMR, FTIR, and hyphenated methods are used to detect and quantify impurities with extended accuracy and sensitivity.This review aims to explore both current and advanced methods for impurity detection, with a focus on recent advancements in analytical techniques and the complexity of formulations. It also examines the challenges of impurity detection, considering existing resources and newly updated regulatory guidelines for impurity control. This review aims to highlight the critical need for improved analytical techniques that minimize errors in impurity detection and enhance accuracy. Stringent regulatory guidelines and advanced analytical techniques like HPLC, MS, and NMR are vital for ensuring drug safety and quality. Continuous innovation in impurity analysis will be crucial to meet evolving standards.
- 1 August 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22 (8)
Harnessing Nature: An Explicative Review on Nano Formulations of Indian Medicinal Plants for Antifungal Applications
Increased cases of fungal infections have become a significant public health concern, exacerbated by improvements in host predisposition characteristics. It is crucial to develop new and innovative methods to prevent drug resistance and combat fungal diseases. To protect humans from newly evolved, disease-causing, drug-resistant fungal infections, it is essential to develop new antifungals in response to the gradual emergence of fungal strains that resist one or more antifungals. While toxicity is a concern, various inorganic and organic chemicals have been developed as antifungals. However, many alternatives, such as medicinal plant extracts with strong antifungal properties and good biocompatibility, have faced challenges due to their limited water solubility, which reduces bioavailability. A promising solution is to use a nanotechnological approach that involves encapsulating or trapping phytochemicals in hydrophilic capping agents, either inorganic or organic. This methodology appears to offer a promising avenue for enhancing the effectiveness of these natural compounds. Recently, the field of medicine has greatly benefited from the use of herbal extracts and their phytomedicines. This article provides an overview of novel approaches that have been investigated to enhance the efficacy of herbal antifungal treatments and reduce the side effects of conventional drugs. These challenges can be addressed through innovative drug delivery strategies that enhance bioavailability and antifungal activity. Additionally, incorporating drugs into innovative systems can significantly reduce their toxicity and enhance the medicinal effects of plant extracts and oils. Therefore, the effective delivery of herbal actives by antifungal agents is facilitated by the use of nanocarriers, such as ethosomes, liposomes, transferosomes, phytosomes, and dendrimers, to the intended location. The methods for delivering herbal nano-formulations to improve antifungal therapy and minimize adverse effects associated with traditional therapy are summarized in the current study. The article also emphasizes the usage of herbal nanocarriers, which have shown the ability to treat a range of fungal illnesses caused by various fungi.
- 1 August 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22 (8)
Harnessing Nature: An Explicative Review on Nano Formulations of Indian Medicinal Plants for Antifungal Applications
Increased cases of fungal infections have become a significant public health concern, exacerbated by improvements in host predisposition characteristics. It is crucial to develop new and innovative methods to prevent drug resistance and combat fungal diseases. To protect humans from newly evolved, disease-causing, drug-resistant fungal infections, it is essential to develop new antifungals in response to the gradual emergence of fungal strains that resist one or more antifungals. While toxicity is a concern, various inorganic and organic chemicals have been developed as antifungals. However, many alternatives, such as medicinal plant extracts with strong antifungal properties and good biocompatibility, have faced challenges due to their limited water solubility, which reduces bioavailability. A promising solution is to use a nanotechnological approach that involves encapsulating or trapping phytochemicals in hydrophilic capping agents, either inorganic or organic. This methodology appears to offer a promising avenue for enhancing the effectiveness of these natural compounds. Recently, the field of medicine has greatly benefited from the use of herbal extracts and their phytomedicines. This article provides an overview of novel approaches that have been investigated to enhance the efficacy of herbal antifungal treatments and reduce the side effects of conventional drugs. These challenges can be addressed through innovative drug delivery strategies that enhance bioavailability and antifungal activity. Additionally, incorporating drugs into innovative systems can significantly reduce their toxicity and enhance the medicinal effects of plant extracts and oils. Therefore, the effective delivery of herbal actives by antifungal agents is facilitated by the use of nanocarriers, such as ethosomes, liposomes, transferosomes, phytosomes, and dendrimers, to the intended location. The methods for delivering herbal nano-formulations to improve antifungal therapy and minimize adverse effects associated with traditional therapy are summarized in the current study. The article also emphasizes the usage of herbal nanocarriers, which have shown the ability to treat a range of fungal illnesses caused by various fungi.
- Open Access
- 1 November 2025
- Published by KEAI Publishing in Letters in Drug Design & Discovery
- Vol. 22 (11)
Quality by design based analytical (RP-HPLC) method development and validation of coenzyme q10 in single and combination with clomiphene citrate: An extensive review
- 1 November 2025
- Published by KEAI Publishing in Letters in Drug Design & Discovery
- Vol. 22 (11)
Open AccessQuality by design based analytical (RP-HPLC) method development and validation of coenzyme q10 in single and combination with clomiphene citrate: An extensive review
- 3 January 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (1)
Novel Aromatic Heterocycles for Dual MAO A and B Inhibitors: A Promising Strategy for Parkinson's Disease Treatment
Recent advancements in the synthesis of aromatic heterocycles have shown promise in the inhibition of monoamine oxidase (MAO) A and B enzymes implicated in the pathophysiology of Parkinson's disease (PD). These heterocyclic compounds are of particular interest due to their structural diversity and significant pharmacological potential.This review discusses various strategies for enhancing MAO inhibitory activity, emphasizing positional modifications. Notable progress includes the development of thiazole‐based and imidazole‐based heterocycles with detailed exploration of their synthetic methodologies and structure–activity relationships. These compounds have demonstrated potential in targeting the metabolism of neurotransmitters, particularly dopamine, which is crucial for managing PD symptoms.The synthesis of aromatic heterocycles targeting MAO A and B inhibition offers a promising pathway for developing novel therapeutics for Parkinson's disease. The structural diversity and pharmacological potential of these compounds, combined with their ability to modulate neurotransmitter levels, present a hopeful avenue for more effective PD management. However, further research, including structure‐based design and in vivo validation, is essential to fully realize their therapeutic efficacy and improve treatment outcomes for Parkinson's disease.
- 3 January 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (1)
Novel Aromatic Heterocycles for Dual MAO A and B Inhibitors: A Promising Strategy for Parkinson's Disease Treatment
Recent advancements in the synthesis of aromatic heterocycles have shown promise in the inhibition of monoamine oxidase (MAO) A and B enzymes implicated in the pathophysiology of Parkinson's disease (PD). These heterocyclic compounds are of particular interest due to their structural diversity and significant pharmacological potential.This review discusses various strategies for enhancing MAO inhibitory activity, emphasizing positional modifications. Notable progress includes the development of thiazole‐based and imidazole‐based heterocycles with detailed exploration of their synthetic methodologies and structure–activity relationships. These compounds have demonstrated potential in targeting the metabolism of neurotransmitters, particularly dopamine, which is crucial for managing PD symptoms.The synthesis of aromatic heterocycles targeting MAO A and B inhibition offers a promising pathway for developing novel therapeutics for Parkinson's disease. The structural diversity and pharmacological potential of these compounds, combined with their ability to modulate neurotransmitter levels, present a hopeful avenue for more effective PD management. However, further research, including structure‐based design and in vivo validation, is essential to fully realize their therapeutic efficacy and improve treatment outcomes for Parkinson's disease.
- Open Access
- 28 January 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 39-44
RP HPLC Method Development for Simultaneous Estimation of Etoricoxib and Thiocolchicoside
A simple, specific and accurate reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for simultaneous estimation of Etoricoxib and Thiocolchicoside in bulk and solid dosage form. Separation was achieved by Zorbax C-18 analytical column having dimension (250mm * 4.6 mm i.d 5.0 µm) using methanol and water (60:40) as mobile phase and flow rate was 0.7ml/min. The detection was carried out at 283 nm wavelength using UV detector. The total chromatographic sample time per analysis was about 14.0 minutes with thiocolchicoside eluted at retention time 3.523 min and etoricoxib eluted at retention time 9.627 min. The method was validated for accuracy, precision, specificity, rapid, reliable and reproducible. LOD and LOQ value for etoricoxib and thiocolchicoside were found to be 0.332, 0.996 ppm and 0976, 0.928 ppm respectively. Regression Equation for Etoricoxib was y = 0.006x + 0.149 and regression equation for thiocolchicoside was Y = 0.030x + 0.086. As the run time was increased the retention time was decreased, so the method is simple and economical and can be adopted by regular quality control in industries and also in research laboratories.
- 28 January 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 39-44
Open AccessRP HPLC Method Development for Simultaneous Estimation of Etoricoxib and Thiocolchicoside
A simple, specific and accurate reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for simultaneous estimation of Etoricoxib and Thiocolchicoside in bulk and solid dosage form. Separation was achieved by Zorbax C-18 analytical column having dimension (250mm * 4.6 mm i.d 5.0 µm) using methanol and water (60:40) as mobile phase and flow rate was 0.7ml/min. The detection was carried out at 283 nm wavelength using UV detector. The total chromatographic sample time per analysis was about 14.0 minutes with thiocolchicoside eluted at retention time 3.523 min and etoricoxib eluted at retention time 9.627 min. The method was validated for accuracy, precision, specificity, rapid, reliable and reproducible. LOD and LOQ value for etoricoxib and thiocolchicoside were found to be 0.332, 0.996 ppm and 0976, 0.928 ppm respectively. Regression Equation for Etoricoxib was y = 0.006x + 0.149 and regression equation for thiocolchicoside was Y = 0.030x + 0.086. As the run time was increased the retention time was decreased, so the method is simple and economical and can be adopted by regular quality control in industries and also in research laboratories.
- 29 August 2019
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 13 (2) , 74-82
Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Background: Asthma is a common ailment with a larger circadian difference. Nocturnal Asthma (NA) is an inconstant exacerbation of asthmatic condition related to the rise in warning sign during the night time and there is a need for its treatment addressing air route alertness and decline in lung functions. These symptoms are linked to sleep or known as circadian events. Chronotherapeutics is a management system based on an in-vivo drug accessibility programmed to check the rhythms of ailment in a direction to improve the therapeutic outcomes by suppressing the side effects. This review aims to provide an overview of NA, chronotherapeutics for the treatment of NA, bilayer tablets, and advanced techniques involved in the fabrication of bilayer tablets. The review also discusses some of the related patents. Methods: Relevant literature about the latest developments and updated information related to NA, chronotherapeutics and bilayer tablets has been very widely searched on different biomedical literature programs such as Google, Web of Science, PubMed portals, etc. Bilayer tablet mediated chronotherapy has gained significant attention and consideration as it is developed and fabricated based on the body’s circadian rhythm. Bilayer tablets can deliver the bioactive compounds at an appropriate time, place as well as amount and site. Results: Available literature advocated that the bilayer matrix tablet containing a single drug in the sustained release film and fast releasing film, may be beneficial for the chronic diseases like asthma, migraine, diabetes, hypertension and inflammation which usually require immediate as well as maintained therapeutic effect. Conclusion: The application of nanotechnology in the arena of medicine will transform the diagnosis and treatment strategies of a wide range of diseases in the upcoming years. The findings of this review confirm the importance of bilayer tablet based chronotherapy in nocturnal asthma.
- 29 August 2019
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 13 (2) , 74-82
Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Background: Asthma is a common ailment with a larger circadian difference. Nocturnal Asthma (NA) is an inconstant exacerbation of asthmatic condition related to the rise in warning sign during the night time and there is a need for its treatment addressing air route alertness and decline in lung functions. These symptoms are linked to sleep or known as circadian events. Chronotherapeutics is a management system based on an in-vivo drug accessibility programmed to check the rhythms of ailment in a direction to improve the therapeutic outcomes by suppressing the side effects. This review aims to provide an overview of NA, chronotherapeutics for the treatment of NA, bilayer tablets, and advanced techniques involved in the fabrication of bilayer tablets. The review also discusses some of the related patents. Methods: Relevant literature about the latest developments and updated information related to NA, chronotherapeutics and bilayer tablets has been very widely searched on different biomedical literature programs such as Google, Web of Science, PubMed portals, etc. Bilayer tablet mediated chronotherapy has gained significant attention and consideration as it is developed and fabricated based on the body’s circadian rhythm. Bilayer tablets can deliver the bioactive compounds at an appropriate time, place as well as amount and site. Results: Available literature advocated that the bilayer matrix tablet containing a single drug in the sustained release film and fast releasing film, may be beneficial for the chronic diseases like asthma, migraine, diabetes, hypertension and inflammation which usually require immediate as well as maintained therapeutic effect. Conclusion: The application of nanotechnology in the arena of medicine will transform the diagnosis and treatment strategies of a wide range of diseases in the upcoming years. The findings of this review confirm the importance of bilayer tablet based chronotherapy in nocturnal asthma.
- 25 December 2017
- Published by Dr. Yashwant Research Labs Pvt. Ltd. in International Journal of Drug Delivery Technology
- Vol. 7 (4)
Liposomes: Current Approaches for Development and Evaluation
Liposomes (50-1000nm) are the part of a specific type of drug delivery system which is non-toxic and biodegradable in nature. That having ability to reduce the toxicity also enhances the therapeutic efficiency and protects the drug which is encapsulated, from the degradation and immediate dilution. These can be prepared by using various techniques like lipid hydration method, sonication method and solvent injecting method etc. But the selection of technique is depended upon the size of liposome which we want. The main disadvantage of this dosage form is it is very much costly and also having time consuming process. But it has major applications in the form of extrusion for homogeneous size, long circulating liposomes, triggered release liposome, remote drug loading, ligand targeted liposomes and containing combination of drugs. These applications are helpful for advanced drug delivery of anticancer, antifungal and anti-inflammatory drug, the delivery of gene medicine, delivery of anaesthetic and antibiotic drug. The newer researches in this field include hybrid liposomes, phototrigerable liposomes which are fabricated to have the improved functionality. These serves as the upcoming novel nanomedicinal chemotherapy technique.
- 25 December 2017
- Published by Dr. Yashwant Research Labs Pvt. Ltd. in International Journal of Drug Delivery Technology
- Vol. 7 (4)
Liposomes: Current Approaches for Development and Evaluation
Liposomes (50-1000nm) are the part of a specific type of drug delivery system which is non-toxic and biodegradable in nature. That having ability to reduce the toxicity also enhances the therapeutic efficiency and protects the drug which is encapsulated, from the degradation and immediate dilution. These can be prepared by using various techniques like lipid hydration method, sonication method and solvent injecting method etc. But the selection of technique is depended upon the size of liposome which we want. The main disadvantage of this dosage form is it is very much costly and also having time consuming process. But it has major applications in the form of extrusion for homogeneous size, long circulating liposomes, triggered release liposome, remote drug loading, ligand targeted liposomes and containing combination of drugs. These applications are helpful for advanced drug delivery of anticancer, antifungal and anti-inflammatory drug, the delivery of gene medicine, delivery of anaesthetic and antibiotic drug. The newer researches in this field include hybrid liposomes, phototrigerable liposomes which are fabricated to have the improved functionality. These serves as the upcoming novel nanomedicinal chemotherapy technique.
- 16 September 2017
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 10 (16) , 22
METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LEVOSULPIRIDE AND RABEPRAZOLE SODIUM: A NEW ANALYTICAL Q-ABSORBANCE RATIO APPROACH
Objective: The aim of the study was to develop a precise, accurate, and rapid ultraviolet spectrophotometric method for simultaneous estimation of levosulpiride (LEVO) and rabeprazole sodium (RBS) in the binary mixture and to validate the method as per ICH guidelines.Method: Estimation of LEVO and RBS was performed by Q-absorbance method. Analysis was performed using the ratio of absorbance at two selected wavelengths, one at iso-absorptive point and other is the absorbance maxima of any one of the components. Single scan spectrum and the overlain spectrum conclude that absorbance maxima of LEVO and RBS are 228 and 291.8 nm, respectively, with a coinciding iso-absorptive point at 255 nm. Method uses a ratio of absorbance for assay at 255 and the second wavelength is 291.8 nm, λmax for RBS. It is also applicable at 228 nm, as the second wavelength.Results: Linearity of LEVO and RBS was found to be 25-125 and 4-36 μg/ml, respectively. The accuracy of the LEVO and RBS was found 99.26% and 99.51%, respectively and Sandell’s sensitivity ranged between 0.0238 and 0.594 μg/cm2. Assay of LEVO (75 mg) and RBS (20 mg) in capsule dosage form was found 99.5% and 98.69% w/w, respectively.Conclusions: The developed method for the estimation of LEVO and RBS in binary mixture were found to be simple, accurate, robust, and reproducible. No interference of excipients and the degraded product was found during the estimation. Therefore, the method can be successfully applied for routine quality control analysis.RBS) in the binary mixture and to validate the method as per ICH guidelines.Method: Estimation of LEVO and RBS was performed by Q-absorbance method. Analysis was performed using the ratio of absorbance at two selected wavelengths, one at iso-absorptive point and other is the absorbance maxima of any one of the components. Single scan spectrum and the overlain spectrum conclude that absorbance maxima of LEVO and RBS are 228 and 291.8 nm respectively with a coinciding iso-absorptive point at 255 nm. Method uses ratio of absorbance for assay at 255 and the second wavelength is 291.8 nm, λmax for RBS. It is also applicable at 228 nm, as the second wavelength.Results: Linearity of LEVO and RBS were found to be 25-125and 4-36 μg/ml respectively. Accuracy of the LEVO and RBS was found 99.26 and 99.51% respectively and Sandell’s sensitivity ranged between 0.0238 and 0.594
- 16 September 2017
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 10 (16) , 22
METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LEVOSULPIRIDE AND RABEPRAZOLE SODIUM: A NEW ANALYTICAL Q-ABSORBANCE RATIO APPROACH
Objective: The aim of the study was to develop a precise, accurate, and rapid ultraviolet spectrophotometric method for simultaneous estimation of levosulpiride (LEVO) and rabeprazole sodium (RBS) in the binary mixture and to validate the method as per ICH guidelines.Method: Estimation of LEVO and RBS was performed by Q-absorbance method. Analysis was performed using the ratio of absorbance at two selected wavelengths, one at iso-absorptive point and other is the absorbance maxima of any one of the components. Single scan spectrum and the overlain spectrum conclude that absorbance maxima of LEVO and RBS are 228 and 291.8 nm, respectively, with a coinciding iso-absorptive point at 255 nm. Method uses a ratio of absorbance for assay at 255 and the second wavelength is 291.8 nm, λmax for RBS. It is also applicable at 228 nm, as the second wavelength.Results: Linearity of LEVO and RBS was found to be 25-125 and 4-36 μg/ml, respectively. The accuracy of the LEVO and RBS was found 99.26% and 99.51%, respectively and Sandell’s sensitivity ranged between 0.0238 and 0.594 μg/cm2. Assay of LEVO (75 mg) and RBS (20 mg) in capsule dosage form was found 99.5% and 98.69% w/w, respectively.Conclusions: The developed method for the estimation of LEVO and RBS in binary mixture were found to be simple, accurate, robust, and reproducible. No interference of excipients and the degraded product was found during the estimation. Therefore, the method can be successfully applied for routine quality control analysis.RBS) in the binary mixture and to validate the method as per ICH guidelines.Method: Estimation of LEVO and RBS was performed by Q-absorbance method. Analysis was performed using the ratio of absorbance at two selected wavelengths, one at iso-absorptive point and other is the absorbance maxima of any one of the components. Single scan spectrum and the overlain spectrum conclude that absorbance maxima of LEVO and RBS are 228 and 291.8 nm respectively with a coinciding iso-absorptive point at 255 nm. Method uses ratio of absorbance for assay at 255 and the second wavelength is 291.8 nm, λmax for RBS. It is also applicable at 228 nm, as the second wavelength.Results: Linearity of LEVO and RBS were found to be 25-125and 4-36 μg/ml respectively. Accuracy of the LEVO and RBS was found 99.26 and 99.51% respectively and Sandell’s sensitivity ranged between 0.0238 and 0.594